◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...
Customize Items

Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.
MENLO PARK, CA
Loading...
Price History
Market Data
Market Cap3.19B
P/E Ratio-
P/B Ratio6.76
EPS-
Dividend Yield-
D/E Ratio0.04
Current Ratio22.37
CurrencyUSD
Key Financial Metrics
-
Revenue
-105.43M
Net Income
-
EPS (Diluted)
-153.36M
Free Cash Flow
Profitability
Gross Margin -
Operating Margin -
Net Profit Margin -
EBITDA -122.05M
Returns & Efficiency
Return on Assets (ROA) -21.6%
Return on Equity (ROE) -22.3%
Dividend Yield -
EPS -
Financial Health
Total Assets 488.62M
Total Debt -
Debt to Equity 0.04x
Current Ratio 22.37
Insider Trading Last 12 months
0
Buys
0
Sells
0
Insiders
Quick Access Filings
10-K
Annual Report

Loading...

10-Q
Quarterly Report

Loading...

8-K
Recent News

Loading...

Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Company Info
IndustryChemicals & Allied Products
HQMENLO PARK, CA
Fiscal Year2025
Peers
915.80B
P/E: --
915.80B
P/E: --
534.79B
P/E: --
357.89B
P/E: --
306.50B
P/E: 632.4
306.50B
P/E: 632.4
276.35B
P/E: --
276.35B
P/E: --
Financial Statistics
Valuation
Market Cap$3.19B
P/E Ratio (TTM)-
Price to Book6.76
EV/Revenue-
EV/EBITDA-
Profitability
Gross Margin-
Operating Margin-
Net Margin-
ROE-22.3%
ROA-21.6%
Leverage & Liquidity
Debt to Equity0.04
Current Ratio22.37
Total Debt-
Total Assets$488.62M
Stockholders' Equity$471.93M
Income Statement (FY 2025)
Revenue-
Gross Profit-
Operating Income$-122.05M
Net Income$-105.43M
EPS (Diluted)-
Cash Flow (FY 2025)
Free Cash Flow$-153.36M
Cash & Equivalents$46.94M
Revenue Growth-
SEC Filings by Category
Insider Trading Activity
Neutral 0 Buys $0 0 Sales $0 0 Exercises $0 Net: $0
InsiderTitleDateTypeSharesPriceValue
Company Information
Business Address855 OAK GROVE AVE.
SUITE 100
MENLO PARK, CA 94025
PhoneN/A
IncorporatedDE, US
EIN363855489
Fiscal Year End1231
Shares Outstanding49.54M
Stockholders' Equity$471.93M
Cash & Equivalents$46.94M
Recent Filings View All
SCHEDULE 13D/A Amended Schedule 13D
Amendment to Schedule 13D
Filed: 2026-05-04
Local
8-K Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-04-30
Local
424B5 Prospectus Supplement
Prospectus supplement filed under Rule 424(b)(5)
Filed: 2026-04-29
Local
424B5 Prospectus Supplement
Prospectus supplement filed under Rule 424(b)(5)
Filed: 2026-04-27
Local
424B5 Prospectus Supplement
Prospectus supplement filed under Rule 424(b)(5)
Filed: 2026-04-27
Local
8-K Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-04-27
Local
424B7 Prospectus (Rule 424b7)
Prospectus filed under Rule 424(b)(7)
Filed: 2026-04-21
Local
144 Proposed Sale Notice
Notice of proposed sale of securities
Filed: 2026-04-15
Local
4 Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-04-15
Local
4 Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-17
Local
4 Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-17
Local
4 Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-17
Local
4 Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-17
Local
4 Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-17
Local
10-K Annual Report
Comprehensive annual financial report with audited statements
Filed: 2026-03-12
Local
Loading...

Loading management data...

Loading...

Loading board of directors...

Loading...

Loading institutional holders...

Loading...

Loading short interest data...

Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Company Profile
General Information
Company NameOruka Therapeutics, Inc.
TickerORKA
Exchange--
SectorManufacturing
IndustryChemicals & Allied Products
HeadquartersMENLO PARK, CA
Fiscal Year2025
Financial Summary
Market Cap3.19B
Revenue-
Net Income-105.43M
P/E Ratio-
EPS-
Net Margin-
ROE-22.3%
Dividend Yield-
Insider Transactions
Loading...
My Notes & Files
Personal Notes
Attached Files
Loading...
NEWS
Loading article...
NEWS
Loading news...
TRENDING
Loading...